Article
Pharmacology & Pharmacy
R. Berardi, A. Berruti, L. Brogelli, P. A. Zucali
Summary: The survey revealed that Italian oncologists tend to use bone-targeted therapy to prevent skeletal-related events in patients with metastatic breast, prostate, or lung cancer, in line with current recommendations.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Oncology
Mashari Alzahrani, Carol Stober, Michelle Liu, Arif Awan, Terry L. Ng, Gregory Pond, Bader Alshamsan, Lisa Vandermeer, Mark Clemons
Summary: This retrospective study evaluated the effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with metastatic breast and castration-resistant prostate cancer. The results showed that the first year after diagnosis of bone metastasis had the highest risk for SSEs.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Chemistry, Multidisciplinary
Yimin Niu, Hongbin Yang, Zhenyan Yu, Cuicui Gao, Shuaishuai Ji, Jie Yan, Lei Han, Qiang Huo, Ming Xu, Yang Liu
Summary: Bone metastasis is a common phenomenon in lung cancer, prostate cancer, and other malignant tumors. In this study, biomineralized metal-organic framework (MOF) nanoparticles carrying protein toxins and combined with RANKL antibody were constructed to effectively treat bone metastases and reduce skeletal-related events (SREs).
Article
Pharmacology & Pharmacy
Andrew H. Tam, Allison J. Schepers, Angel Qin, Victoria R. Nachar
Summary: This study is the first to examine the extended-interval dosing of zoledronic acid in metastatic lung cancer patients. The incidence and time to skeletal-related events at 1 year were similar between the Q12wk and Q4wk dosing groups, but the Q12wk dosing group had a longer overall survival time.
ANNALS OF PHARMACOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Paola Maroni, Paola Bendinelli, Anita Ferraretto, Giovanni Lombardi
Summary: Bone metastases are a major issue in the progression of breast cancer, posing a significant treatment challenge. Interleukin-11 plays a key role in bone metastasis and could be a candidate for anti-metastatic therapy. Further research is needed to understand the contribution of different cytokines in breast cancer progression and develop effective therapeutic strategies.
Article
Oncology
Go Saito, Takahiro Ebata, Tsukasa Ishiwata, Shunichiro Iwasawa, Ichiro Yoshino, Yuichi Takiguchi, Koichiro Tatsumi
Summary: This study reviewed the medical records of 238 consecutive NSCLC patients treated with BMAs and identified risk factors such as performance status, gender, and type of bone-modifying agent that can affect the occurrence of SREs. Careful observation is needed for patients with these identified risk factors.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Georg Herget, Babak Saravi, Eugenia Schwarzkopf, Mara Wigand, Norbert Suedkamp, Hagen Schmal, Markus Uhl, Gernot Lang
Summary: Skeletal-related events due to bone metastases significantly impact cancer patient morbidity and mortality. This study investigated clinicopathological characteristics, metastasis-free survival, and SREs in patients referred to a tertiary orthopedic and trauma center. Breast and lung cancer were most common in women, while lung and prostate cancer were most common in men, with age and primary cancer grading showing prognostic relevance.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Orthopedics
Hilal Yagar, Mahmut Nedim Aytekin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Recep Ozturk, Buelent Yalcin
Summary: This study investigated the relationship between metastatic volume measurement, skeletal-related events, and survival in breast cancer patients with bone metastases. The results suggest that measuring metastatic volume may be a critical factor in evaluating the survival of these patients.
JOINT DISEASES AND RELATED SURGERY
(2023)
Article
Oncology
Hirotaka Miyashita, Christina Cruz, Vaibhav Patel
Summary: This study analyzed clinical data from patients with bone metastatic prostate cancer and identified potential risk factors for skeletal-related events (SREs) such as history of SREs, Gleason score >= 7, elevated serum alkaline phosphatase, and high urine N-telopeptide cross-links/creatinine ratio.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Multidisciplinary Sciences
Baha Zengel, Mustafa Kilic, Funda Tasli, Cenk Simsek, Murat Karatas, Ozlem Ozdemir, Demet Cavdar, Raika Durusoy, Kadir Koray Bas, Adam Uslu
Summary: This study investigated the clinical course of patients with breast cancer with OMBD, finding that OMBD may be a different disease than breast cancer with isolated bone metastases. The high risk of developing OMBD, especially following locoregional recurrence, increases the importance of locoregional therapy in large T and N stage tumors.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Ruohan Yang, Lin Jia, Guanyu Lu, Zheng Lv, Jiuwei Cui
Summary: Symptomatic bone marrow metastasis in breast cancer is rare and has a poor prognosis. Chemotherapy is the primary treatment, but its efficacy is limited, resulting in dose reduction and decreased quality of life. This study aimed to explore the clinicopathological characteristics, treatment modalities, and prognosis of breast cancer patients with bone marrow metastasis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Naoko Tanda, Hiroshi Tada, Jumpei Washio, Nobuhiro Takahashi, Takanori Ishida, Takeyoshi Koseki
Summary: Alcohol sensitivity may be a prognostic risk factor for bone metastases in primary operable breast cancer patients. More detailed genetic investigations and metabolic analyses are needed to confirm these findings.
Review
Cell Biology
Sharon Russo, Federica Scotto di Carlo, Fernando Gianfrancesco
Summary: Osteoclasts play an important role in bone remodeling, but they are also involved in bone tumors and metastases. They increase the aggressiveness of primary tumors and promote metastasis of breast and pancreas cancer cells to the bone. Additionally, osteoclasts are responsible for reactivating dormant cancer cells in the bone marrow, leading to overt metastasis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Tulasi Ponnapakkam, Muralidharan Anbalagan, Robert E. Stratford, Brian G. Rowan, Robert C. Gensure
Summary: Novel bone-targeted PTHrP antagonists have shown success in reducing tumor burden and osteolytic destruction of breast cancer cells in mice, as well as inducing apoptosis in vitro, demonstrating their potential as a new treatment paradigm for breast cancer bone metastases.
Article
Medicine, General & Internal
Lucija Kovacevic, Mislav Cavka, Zlatko Marusic, Elvira Kresic, Andrija Stajduhar, Lora Grbanovic, Ivo Dumic-Cule, Maja Prutki
Summary: CT-guided bone lesion biopsy has high diagnostic accuracy in confirming bone metastases and assessing hormone receptor status in patients with breast cancer. This study suggests that CT-guided biopsy is crucial for patients with breast cancer and suspicious bone lesions.